345 - CCS/NATIONAL ADVISORY COMMITTEE JOINT STATEMENT ON BLOOD UTILIZATION/TRANSFUSION FOR PATIENTS WITH CARDIOVASCULAR DISEASE

Saturday, October 25, 2025

2:00pm - 3:00pm ET

Room:304AB

Target Audience: General: All cardiovascular (clinical and research) health professionals, Internists, Trainee (clinical)

Co-Chair(s)

GS

Greg Schnell, MD, FRCPC

CLINICIAN
CCS, CANCARE, CSE
Libin Cardiovascular Institute
AS

Andrew Shih, MD. FRCPC, DRCPSC, MSc

Presenter(s)

GS

Greg Schnell, MD, FRCPC

CLINICIAN
CCS, CANCARE, CSE
Libin Cardiovascular Institute
AS

Andrew Shih, MD. FRCPC, DRCPSC, MSc

Moderator(s)

CG

Carolyn Gall Casey, BASc

Director Guidelines and Knowledge Translation
Canadian Cardiovascular Society

Administrator ( Guidelines Submission Only )(s)

CG

Carolyn Gall Casey, BASc

Director Guidelines and Knowledge Translation
Canadian Cardiovascular Society

Planning Committee Member(s)

GS

Greg Schnell, MD, FRCPC

CLINICIAN
CCS, CANCARE, CSE
Libin Cardiovascular Institute

Workshop Description: This workshop will review the joint statement from the Canadian Cardiovascular Society (CCS)/National Advisory Committee on Blood and Blood Products regarding best practices for blood utilization and transfusion in patients with cardiovascular disease. It will provide evidence-based recommendations for transfusion thresholds in the setting of acute coronary syndromes. Emphasis will be placed on aligning clinical decision-making with updated national guidance to ensure patient safety and optimize outcomes.

Learning Objectives:

At the end of this session participants will be able to:

apply currently published data into an approach for blood transfusion thresholds in patients with cardiovascular disease;
evaluate the risks, benefits, and systems factors of transfusion in various cardiovascular patient populations; and
incorporate blood product management best practices, including transfusion and alternatives, into multidisciplinary cardiovascular care pathways.